-
- Leire Bejarano
- 1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
-
- Marta J.C. Jordāo
- 1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
-
- Johanna A. Joyce
- 1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
説明
<jats:title>Abstract</jats:title> <jats:sec> <jats:title /> <jats:p>Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies. Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix. We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.</jats:p> </jats:sec>
収録刊行物
-
- Cancer Discovery
-
Cancer Discovery 11 (4), 933-959, 2021-04-01
American Association for Cancer Research (AACR)